<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159263</url>
  </required_header>
  <id_info>
    <org_study_id>BU-039-0005</org_study_id>
    <nct_id>NCT00159263</nct_id>
  </id_info>
  <brief_title>Effect of Symbicort on GR Localisation in Asthma</brief_title>
  <official_title>Effect of Symbicort on GR (Glucocorticoid Receptor) Translocation in Induced Sputum in Comparison With Budesonide, Formoterol and Placebo. A Single Dose Exploratory Study in Patients With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate a possible interaction between formoterol and budesonide on GR-translocation
      and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the
      effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect
      of the study drugs on exhaled NO (bronchial and alveolar fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination therapy with inhaled corticosteroids (ICS) and long-acting β(2)-adrenergic
      agonists (LABA) is reported to have superior effects on controlling asthma symptoms to ICS
      alone; however, there is no molecular-based evidence to explain the clinical effects. Here,
      the effect of the ICS/LABA combination was compared with ICS on glucocorticoid receptor (GR)
      activation in sputum macrophage.

      In a randomised, double-blind cross-over placebo-controlled 6-visit study, 10 patients with
      mild asthma were given placebo, formoterol (Oxis(®) 12 μg), budesonide (Pulmicort(®) 200 μg
      :BUD200, or 800 μg :BUD800), or budesonide/formoterol combination (Symbicort(®)) as a single
      100/6 μg (SYM100) or double 200/12 μg (SYM200) dose. Sputum macrophages were separated by
      plate adhesion from induced sputum. GR binding to the glucocorticoid-response elements on
      oligonucleotides (GR-GRE binding) was evaluated by ELISA. mRNA expression of MAP-kinase
      phosphatase (MKP)-1 and IL-8 were measured by quantitative RT-PCR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in GR-GRE Binding</measure>
    <time_frame>1-2h</time_frame>
    <description>The GR-GRE binding is the glucocorticoid receptor (GR) DNA binding affinity. GR-GRE activity as assed by enzyme-immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in MKP-1 mRNA</measure>
    <time_frame>1-2h</time_frame>
    <description>Changes in MKP-1 mRNA measured by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL8 mRNA</measure>
    <time_frame>1-2h</time_frame>
    <description>Measured by PCR</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxis(®) 12 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmicort(®) 200 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmicort(®) 800 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/formoterol combination single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 100/6 μg SYM100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/formoterol combination double</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double 200/12 μg SYM200</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Dry powder inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Inhalant Powder</intervention_name>
    <description>12ug</description>
    <arm_group_label>Formoterol</arm_group_label>
    <other_name>Oxis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Powder</intervention_name>
    <description>Inhaler</description>
    <arm_group_label>Budesonide high dose</arm_group_label>
    <arm_group_label>Budesonide low dose</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide and Formoterol Product</intervention_name>
    <description>Combination Inhaler, Symbicort</description>
    <arm_group_label>Budesonide/formoterol combination double</arm_group_label>
    <arm_group_label>Budesonide/formoterol combination single</arm_group_label>
    <other_name>Combination Inhaler, Symbicort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild steroid-naïve asthma (ATS criteria) of either sex with FEV1 &gt;70 %
             pred

          -  Able to produce sputum after sputum induction

          -  Exhaled NO (flow 50 ml/s) ≥ 20 ppb

          -  Written informed consent

        Exclusion Criteria:

          -  Current upper respiratory tract infections

          -  Use of inhaled and/or oral GCS within 4 weeks prior to visit 1

          -  Treatment with antileukotrienes, theophylline, tiotropium and ipratropium within 2
             weeks prior to screening visit

          -  Hypersensitivity to any of the investigational drugs or lactose

          -  Use of any beta blocking agent (including eye-drops)

          -  Women who are pregnant, breast-feeding or planning a pregnancy during the study. Women
             must be postmenopausal (at least one year must have passed after the last
             menstruation), surgically sterile or using acceptable contraceptives, as judged by the
             investigator

          -  Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than
             asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine,
             metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of
             the investigator, may either put the subject at risk because of participation in the
             study, or may influence the results of the study, or the subjects ability to
             participate in the study

          -  Inability to tolerate temporary withdrawal of bronchodilatory therapy

          -  Subjects not considered capable, as judged by the investigator, of following
             instructions of the study, e.g. because of a history of alcohol or drug abuse or any
             other reason

          -  Previous randomization in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergei A Kharitonov, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Essilfie-Quaye S, Ito K, Ito M, Kharitonov SA, Barnes PJ. Comparison of Symbicort® versus Pulmicort® on steroid pharmacodynamic markers in asthma patients. Respir Med. 2011 Dec;105(12):1784-9. doi: 10.1016/j.rmed.2011.08.020. Epub 2011 Sep 7.</citation>
    <PMID>21903370</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>July 8, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2019</results_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Glucocorticoid</keyword>
  <keyword>Long-acting beta2-adrenoceptor</keyword>
  <keyword>Inhaled corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10patient recruited mild asthma</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>first intervention is placebo, then Formoterol, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double</description>
        </group>
        <group group_id="P2">
          <title>Formoterol</title>
          <description>First intervention is formoterol, then placebo, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double</description>
        </group>
        <group group_id="P3">
          <title>Budesonide Low Dose</title>
          <description>First intervention is Budesonide low dose, then placebo, then Formoterol, then Budesonide high dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double</description>
        </group>
        <group group_id="P4">
          <title>Budesonide High Dose</title>
          <description>First intervention is Budesonide high dose, then placebo, then Formoterol, then Budesonide low dose, then Budesonide/Formoterol single, then Budesonide/Formoterol double</description>
        </group>
        <group group_id="P5">
          <title>Budesonide/Formoterol Single</title>
          <description>First intervention is Budesonide/Formoterol single, then placebo, then Formoterol, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol double</description>
        </group>
        <group group_id="P6">
          <title>Budesonide/Formoterol Double</title>
          <description>First intervention is Budesonide/Formoterol double, then placebo, then Formoterol, then Budesonide low dose, then Budesonide high dose, then Budesonide/Formoterol single</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fourth Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fifth Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sixth Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Crossover study, same volunteers in all arm, received the following interventions: formoterol, Budesonide low and high dose, or combination of these</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in GR-GRE Binding</title>
        <description>The GR-GRE binding is the glucocorticoid receptor (GR) DNA binding affinity. GR-GRE activity as assed by enzyme-immunosorbent assay</description>
        <time_frame>1-2h</time_frame>
        <population>Crossover, each patient had all treatments</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo
Placebos: Dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Oxis(®) 12 μg
Formoterol Inhalant Powder: 12ug</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Low Dose</title>
            <description>Pulmicort(®) 200 μg
Budesonide Powder: Inhaler</description>
          </group>
          <group group_id="O4">
            <title>Budesonide High Dose</title>
            <description>Pulmicort(®) 800 μg
Budesonide Powder: Inhaler</description>
          </group>
          <group group_id="O5">
            <title>Budesonide/Formoterol Combination Single</title>
            <description>single 100/6 μg SYM100
Budesonide and Formoterol Product: Combination Inhaler, Symbicort</description>
          </group>
          <group group_id="O6">
            <title>Budesonide/Formoterol Combination Double</title>
            <description>double 200/12 μg SYM200
Budesonide and Formoterol Product: Combination Inhaler, Symbicort</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in GR-GRE Binding</title>
          <description>The GR-GRE binding is the glucocorticoid receptor (GR) DNA binding affinity. GR-GRE activity as assed by enzyme-immunosorbent assay</description>
          <population>Crossover, each patient had all treatments</population>
          <units>GRE activity (OD)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.5" upper_limit="2"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.3" upper_limit="2.6"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.7" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.3" lower_limit="1.1" upper_limit="7"/>
                    <measurement group_id="O5" value="3.5" lower_limit="1.3" upper_limit="6.1"/>
                    <measurement group_id="O6" value="3" lower_limit="1.5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Friedman ANOVA followed Dunn`s pairwise comparisons</non_inferiority_desc>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in MKP-1 mRNA</title>
        <description>Changes in MKP-1 mRNA measured by PCR</description>
        <time_frame>1-2h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo
Placebos: Dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Oxis(®) 12 μg
Formoterol Inhalant Powder: 12ug</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Low Dose</title>
            <description>Pulmicort(®) 200 μg
Budesonide Powder: Inhaler</description>
          </group>
          <group group_id="O4">
            <title>Budesonide High Dose</title>
            <description>Pulmicort(®) 800 μg
Budesonide Powder: Inhaler</description>
          </group>
          <group group_id="O5">
            <title>Budesonide/Formoterol Combination Single</title>
            <description>single 100/6 μg SYM100
Budesonide and Formoterol Product: Combination Inhaler, Symbicort</description>
          </group>
          <group group_id="O6">
            <title>Budesonide/Formoterol Combination Double</title>
            <description>double 200/12 μg SYM200
Budesonide and Formoterol Product: Combination Inhaler, Symbicort</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in MKP-1 mRNA</title>
          <description>Changes in MKP-1 mRNA measured by PCR</description>
          <units>MKP1/GNB2L1 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.1" upper_limit="1"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="44"/>
                    <measurement group_id="O3" value="3" lower_limit="2" upper_limit="70"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="51"/>
                    <measurement group_id="O5" value="5" lower_limit="3" upper_limit="150"/>
                    <measurement group_id="O6" value="5" lower_limit="3" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Friedman Anova</non_inferiority_desc>
            <p_value>0.01</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL8 mRNA</title>
        <description>Measured by PCR</description>
        <time_frame>1-2h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo
Placebos: Dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Formoterol</title>
            <description>Oxis(®) 12 μg
Formoterol Inhalant Powder: 12ug</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Low Dose</title>
            <description>Pulmicort(®) 200 μg
Budesonide Powder: Inhaler</description>
          </group>
          <group group_id="O4">
            <title>Budesonide High Dose</title>
            <description>Pulmicort(®) 800 μg
Budesonide Powder: Inhaler</description>
          </group>
          <group group_id="O5">
            <title>Budesonide/Formoterol Combination Single</title>
            <description>single 100/6 μg SYM100
Budesonide and Formoterol Product: Combination Inhaler, Symbicort</description>
          </group>
          <group group_id="O6">
            <title>Budesonide/Formoterol Combination Double</title>
            <description>double 200/12 μg SYM200
Budesonide and Formoterol Product: Combination Inhaler, Symbicort</description>
          </group>
        </group_list>
        <measure>
          <title>IL8 mRNA</title>
          <description>Measured by PCR</description>
          <units>IL8/GNB2L1 ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.1" upper_limit="1.7"/>
                    <measurement group_id="O2" value="4" lower_limit="0.1" upper_limit="20"/>
                    <measurement group_id="O3" value="4" lower_limit="0.1" upper_limit="20"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.1" upper_limit="1.3"/>
                    <measurement group_id="O5" value="0.2" lower_limit="0.1" upper_limit="0.7"/>
                    <measurement group_id="O6" value="0.2" lower_limit="0.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Friedman Anova</non_inferiority_desc>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients who received placebo treatment</description>
        </group>
        <group group_id="E2">
          <title>Formoterol</title>
          <description>Patients who received Formoterol treatment</description>
        </group>
        <group group_id="E3">
          <title>Budesonide Low Dose</title>
          <description>Patients who received Budesonide low dose treatment</description>
        </group>
        <group group_id="E4">
          <title>Budesonide High Dose</title>
          <description>Patients who received Budesonide high dose treatment</description>
        </group>
        <group group_id="E5">
          <title>Budesonide/Formoterol Single</title>
          <description>Patients who received Budesonide/Formoterol single dose treatment</description>
        </group>
        <group group_id="E6">
          <title>Budesonide/Formoterol Double</title>
          <description>Patients who received Budesonide/Formoterol double dose treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Barnes</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 7594 7959</phone>
      <email>p.j.barnes@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

